First oral short-course treatment for MS

Mavenclad (cladribine) is licensed for the treatment of adults with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.

by Lisa Lytle
The recommended cumulative dose of Mavenclad is 3.5mg/kg over 2 years, administered as 1 or 2 tablets daily for 4 or 5 days at the start of month 1 and repeated at the start of month 2 of each treatment year. | SCIENCE PHOTO LIBRARY
The recommended cumulative dose of Mavenclad is 3.5mg/kg over 2 years, administered as 1 or 2 tablets daily for 4 or 5 days at the start of month 1 and repeated at the start of month 2 of each treatment year. | SCIENCE PHOTO LIBRARY

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package